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the international community can sustain and expand this
momentum to develop a comprehensive control effort in all
disease-endemic countries.
doi:10.1016/j.ijid.2008.05.13334 13th Internat
Conclusion: JE patients were found in all study sites,
nd sequelae were found in a high proportion of patients. A
ational program of JE vaccination is certainly worth con-
ideration.
oi:10.1016/j.ijid.2008.05.131
5.003
he Landscape of New Vaccines for Japanese Encepha-
itis: Country-Level Strategies for Introduction
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Epidemiology Unit, Ministry of Health, Colombo, Sri Lanka
Consultant Epidemiologist, Ministry of Health, Colombo,
ri Lanka
he ﬁrst recorded major outbreak of Japanese encephalitis
JE) in Sri Lanka occurred in 1985—86 with 385 cases and 64
eaths in the North Central province. Outbreaks occurred
n 1986—87 and 1987—88, the latter being the largest with
12 cases and 192 deaths in three adjoining districts. Cases
ccurred in rice cultivating areas with a network of irrigation
anals supported by seasonal, moderate to heavy rainfall.
hildren aged 5— and young adults aged 20—24 years were
redominantly affected.
JE was also spreading to new areas with previously
ow transmission. To cope with this emerging challenge,
he Ministry of Health’s Epidemiology Unit initiated phased
E immunization in 1988. Children aged 1—10 years were
ffered three primary doses and a booster of inactivated
accine in the interpandemic period through a campaign
pproach. Over the years, JE incidence decreased as immu-
isation coverage increased. However, cases and occasional
utbreaks were reported in other districts where immuniza-
ion was not carried out, and the programme ultimately
xpanded to 18 districts.An increasing trend of adverse
vents following immunization with the inactivated JE vac-
ine threatened repercussions to the programme. Another
bstacle was the increasing cost of the inactivated vaccine-
S$4.50 per dose in 2006, a prohibitive factor to programme
ustainability. Identifying an affordable, safe and immuno-
enic vaccine alternative was a high priority.
The live, attenuated SA 14-14-2 JE vaccine (LJEV)
ppeared to be an appropriate, low cost, safe and potent
lternative. With support from PATH, the Epidemiology Unit
nitiated a clinical trial in 2007 to ascertain the safety and
mmunogenicity of LJEV. Based on preliminary results, the
overnment decided to introduce LJEV in place of the inacti-
ated vaccine, hopefully expanding to routine EPI very soon.
Currently, the Ministry of Health is negotiating a public
ector price for procurement of LJEV and ﬁnalizing the rec-
mmended schedule. Cost savings from transitioning to LJEV
ill enable the introduction of new vaccines and will extend
he JE immunization programme to adults in high endemic
reas.
oi:10.1016/j.ijid.2008.05.132l Congress on Infectious Diseases Abstracts (Invited Papers)
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JE is the leading cause of viral neurological infection
encephalitis) in the Asian region, primarily affecting chil-
ren aged 1-15 years in rural areas. JE vaccination has
een successful in effectively controlling the disease in
any countries where JE was identiﬁed as a public health
roblem, often linked to epidemic manifestation. These
xperiences show the way to successful JE control and,
ecently, several additional countries have started to intro-
uce JE vaccination.
Today, there is great opportunity to sustain and expand
omentum for JE control through vaccination, building on
ecent advances achieved through country, WHO and part-
ers’ efforts, in particular PATH. Increasingly, countries are
stablishing surveillance to document the burden of disease.
ive, attenuated vaccine has shown great potential in pre-
enting disease and is becoming available in large volume
t a highly preferential public-sector price. Additionally,
romising JE vaccines under development should become
icensed for pediatric use during the coming years. More-
ver, cost-effectiveness analysis gives favorable ﬁgures in
any country settings (estimated 75$/DALY loss averted for
AVI-eligible countries), providing a strong rationale for vac-
ine introduction. Most important, however, is public and
overnment recognition of the JE problem, and the will to
ake action.
To advance sustainable introduction of JE vaccination
here it matters, priorities include documentation of dis-
ase burden -in particular in countries with no visible
pidemics-and the establishment of a public sector report-
ng system. Building local capacity for strengthening JE
urveillance, including quality-assured diagnostic laborato-
ies, is key. The decision on vaccine introduction and optimal
mmunization strategy has to follow a rationale process
s recommended for any other vaccine, with a particular
mphasis on cost-effectiveness analysis and ﬁnancial and
anagerial planning to sustain the effort beyond initial cam-
aigns. This includes an assured vaccine procurement plan
nd an AEFI system to monitor vaccine safety.
Countries have shown leadership in introducing JE vac-
ination. Targeted ﬁnancial and technical support from
